Profiel
Arup Roy has worked as a Director at Seraxis, Inc. and Seraxis Holdings, Inc. He has no middle name and his full name is Mr. Roy.
Actieve functies van Arup Roy
| Bedrijven | Functie | Begin |
|---|---|---|
Seraxis Holdings, Inc.
 Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Directeur/Bestuurslid | - |
Seraxis, Inc.
 Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Seraxis Holdings, Inc.
Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Finance |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Health Technology |
